RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK (landiolol) for use in pediatric patients (from birth to This press release features ...

RESET-PSVT is intended to generate prospective evidence to inform the real-world use of recently approved CARDAMYST and demonstrate its potential impact on the acute management of PSVT. Results are ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Sick sinus syndrome (SSS) is a heart rhythm problem that affects your heart's natural pacemaker. You may develop symptoms of SSS like dizziness, fainting, and fatigue. Treatment may include lifestyle ...

The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...

Inappropriate sinus tachycardia (IST) is an arrhythmia characterized by rapid sinus rates of over 100 bpm at rest. The mechanisms underlying this often-debilitating condition are not fully understood.

Credit: AOP Health. Rapiblyk is supplied as a lyophilized powder containing 280mg of landiolol (equivalent to 300mg of landiolol HCl) in a single-dose vial. It is intended for use in intensive care, ...

Background Inappropriate sinus tachycardia (IST) is characterized by persistent and disproportional elevation of heart rate (HR). Ivabradine has been successfully used in some patients. Methods Twenty ...